Before a drug reaches the pharmacy shelf, it passes through a sequence of human studies designed to answer two questions: does it work, and is it safe? That sequence is the clinical trial, a research study conducted in volunteers under strict ethical and regulatory oversight. The path from first-in-human to approval typically takes six to ten years and involves thousands of participants.

Trials move through phases. Phase I tests safety and dosing in a small group, often 20 to 80 people. Phase II looks at efficacy and side effects in a few hundred. Phase III confirms efficacy in a large population, sometimes thousands, and compares the drug to standard treatment or placebo. Phase IV happens after approval, tracking long-term effects in the real world. Each phase can fail, and most drugs that enter Phase I never reach the market.

Key elements of any trial:

• Protocol. A written plan that specifies everything from eligibility to analysis.
• Informed consent. Participants must understand risks before enrolling.
• Randomization. Assigning treatments by chance reduces bias.
• Blinding. Keeping participants and researchers unaware of assignments.
• Oversight. An institutional review board monitors ethics; a data safety monitoring board watches outcomes.

Results are published whether positive or negative. The trial registry keeps a public record of what was studied.